These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22549947)

  • 21. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
    Schmeler KM; Vadhan-Raj S; Ramirez PT; Apte SM; Cohen L; Bassett RL; Iyer RB; Wolf JK; Levenback CL; Gershenson DM; Freedman RS
    Gynecol Oncol; 2009 May; 113(2):210-5. PubMed ID: 19264351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
    Appleton K; Mackay HJ; Judson I; Plumb JA; McCormick C; Strathdee G; Lee C; Barrett S; Reade S; Jadayel D; Tang A; Bellenger K; Mackay L; Setanoians A; Schätzlein A; Twelves C; Kaye SB; Brown R
    J Clin Oncol; 2007 Oct; 25(29):4603-9. PubMed ID: 17925555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
    Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
    Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
    Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
    Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
    van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
    Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
    Hirte H; Oza A; Swenerton K; Ellard SL; Grimshaw R; Fisher B; Tsao M; Seymour L
    Gynecol Oncol; 2010 Sep; 118(3):308-12. PubMed ID: 20646751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
    Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
    Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
    Wong-Brown MW; van der Westhuizen A; Bowden NA
    BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
    J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
    Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.